Iovance Biotherapeutics Statistics
Share Statistics
Iovance Biotherapeutics has 333.93M
shares outstanding. The number of shares has increased by 17.17%
in one year.
| Shares Outstanding | 333.93M |
| Shares Change (YoY) | 17.17% |
| Shares Change (QoQ) | 7.58% |
| Owned by Institutions (%) | 79.63% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 101,116 |
| FTD / Avg. Volume | 0.8% |
Short Selling Information
The latest short interest is 77.02M, so 23.06% of the outstanding
shares have been sold short.
| Short Interest | 77.02M |
| Short % of Shares Out | 23.06% |
| Short % of Float | 25.26% |
| Short Ratio (days to cover) | 3.03 |
Valuation Ratios
The PE ratio is -5.76 and the forward
PE ratio is -2.48.
Iovance Biotherapeutics's PEG ratio is
0.18.
| PE Ratio | -5.76 |
| Forward PE | -2.48 |
| PS Ratio | 13.07 |
| Forward PS | 0.5 |
| PB Ratio | 3.02 |
| P/FCF Ratio | -5.89 |
| PEG Ratio | 0.18 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Iovance Biotherapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.74,
with a Debt / Equity ratio of 0.08.
| Current Ratio | 3.74 |
| Quick Ratio | 3.31 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | -0.17 |
| Debt / FCF | -0.16 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $195,787.59 |
| Profits Per Employee | $-444,125.3 |
| Employee Count | 838 |
| Asset Turnover | 0.18 |
| Inventory Turnover | 2.41 |
Taxes
| Income Tax | -2.83M |
| Effective Tax Rate | 0.75% |
Stock Price Statistics
The stock price has increased by -77.65% in the
last 52 weeks. The beta is 1.06, so Iovance Biotherapeutics's
price volatility has been higher than the market average.
| Beta | 1.06 |
| 52-Week Price Change | -77.65% |
| 50-Day Moving Average | 2.79 |
| 200-Day Moving Average | 6.78 |
| Relative Strength Index (RSI) | 36.31 |
| Average Volume (20 Days) | 12,691,504 |
Income Statement
In the last 12 months, Iovance Biotherapeutics had revenue of 164.07M
and earned -372.18M
in profits. Earnings per share was -1.28.
| Revenue | 164.07M |
| Gross Profit | 40.08M |
| Operating Income | -395.28M |
| Net Income | -372.18M |
| EBITDA | -351.67M |
| EBIT | -395.28M |
| Earnings Per Share (EPS) | -1.28 |
Full Income StatementBalance Sheet
The company has 115.69M in cash and 58.26M in
debt, giving a net cash position of 57.43M.
| Cash & Cash Equivalents | 115.69M |
| Total Debt | 58.26M |
| Net Cash | 57.43M |
| Retained Earnings | -2.38B |
| Total Assets | 966.74M |
| Working Capital | 389.96M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -352.98M
and capital expenditures -11.07M, giving a free cash flow of -364.05M.
| Operating Cash Flow | -352.98M |
| Capital Expenditures | -11.07M |
| Free Cash Flow | -364.05M |
| FCF Per Share | -1.26 |
Full Cash Flow StatementMargins
Gross margin is 24.43%, with operating and profit margins of -240.92% and -226.84%.
| Gross Margin | 24.43% |
| Operating Margin | -240.92% |
| Pretax Margin | -228.56% |
| Profit Margin | -226.84% |
| EBITDA Margin | -214.34% |
| EBIT Margin | -240.92% |
| FCF Margin | -221.88% |
